新型自然杀伤细胞疗法治疗血液系统恶性肿瘤和实体瘤：2024 年 ASCO 最新进展。
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024.
机构信息
Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310000, P.R. China.
Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, USA.
出版信息
J Hematol Oncol. 2024 Jul 29;17(1):57. doi: 10.1186/s13045-024-01575-0.
Natural killer (NK) cell-based therapies have made great progress in treating both hematological and solid tumors. Their unique mechanism of action does not rely on antigen presentation to recognize and eliminate tumor cells, making them a promising approach for cancer immunotherapy. In this review, we present a comprehensive summary of the latest clinical data of the novel NK cell-based therapies from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the potential of these advancements to revolutionize the treatment of hematologic malignancies and solid tumors.
基于自然杀伤 (NK) 细胞的疗法在治疗血液系统肿瘤和实体瘤方面取得了重大进展。它们独特的作用机制不依赖于抗原呈递来识别和消除肿瘤细胞，这使它们成为癌症免疫治疗的一种很有前途的方法。在这篇综述中，我们全面总结了 2024 年美国临床肿瘤学会 (ASCO) 年会上新型基于 NK 细胞的疗法的最新临床数据，强调了这些进展有可能彻底改变血液系统恶性肿瘤和实体瘤的治疗。
Zotero 插件